Core Insights - Haocen Medical's stock closed at 2.61 yuan, up 3.16%, with a latest price-to-book ratio of 4.90 and a total market capitalization of 2.192 billion yuan [1] - As of September 30, 2024, Haocen Medical had 44,932 shareholders, an increase of 3,565 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company primarily engages in oral medical services and the research, production, and sales of permanent magnet switches and high/low voltage switchgear products, with key offerings including medical oral services, industrial switch products, and credit big data software services [1] Financial Performance - For the third quarter of 2024, Haocen Medical reported operating revenue of 635 million yuan, a year-on-year increase of 21.27%, and a net profit of 13.4967 million yuan, reflecting a year-on-year decrease of 17.31%, with a gross profit margin of 47.97% [1] - The company's price-to-earnings (P/E) ratio (TTM) is -22.56, while the industry average is 46.79, indicating a significant divergence from industry norms [2] - The total market capitalization of Haocen Medical is 2.192 billion yuan, compared to the industry median of 4.888 billion yuan [2]

皓宸医疗科技股份有限公司主要从事口腔医疗服务以及永磁开关及高低压开关成套设备产品的研发、生 产和销售。其主要产品有医疗口腔服务、实业开关产品、征信大数据软件服务。 4月9日，皓宸医疗今日收盘2.45元，上涨2.08%，最新市净率4.60，总市值20.58亿元。 资金流向方面，4月9日，皓宸医疗主力资金净流入106.30万元，近5日总体呈流出状态，5日共流出 774.66万元。 最新一期业绩显示，2024年三季报，公司实现营业收入6.35亿元，同比21.27%；净利润1349.67万元， 同比-17.31%，销售毛利率47.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)9皓宸医疗-21.18-21.814.6020.58亿行业平均 45.7741.333.33140.72亿行业中值43.7835.472.4544.48亿1普瑞眼科-192.3424.042.9064.41亿2何氏眼 科-144.5344.311.4628.16亿3迪安诊断-92.5027.851.2185.62亿4光正眼科-84.88201.676.8418.66亿5创新医 疗-78.10-109.142.0337.42亿6南 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)9皓宸医疗-21.61-22.254.6921.00亿行业平均 45.7240.943.28142.68亿行业中值41.8333.882.5543.24亿1普瑞眼科-173.2621.662.6258.02亿2何氏眼 科-136.5041.851.3726.60亿3光正眼科-86.53205.596.9719.03亿4迪安诊断-85.2825.671.1278.93亿5南华生 物-80.12-105.4311.9529.70亿6创新医疗-78.19-109.272.0337.47亿7国际医学-31.81-30.933.12113.92亿8嘉和 美康-25.49-25.492.1438.24亿10美迪西-11.36-11.361.5335.89亿11和元生物-10.03-10.031.7432.58亿 来源：金融界 皓宸医疗科技股份有限公司主要从事口腔医疗服务以及永磁开关及高低压开关成套设备产品的研发、生 产和销售。其主要产品有医疗口腔服务、实业开关产品、征信大数据软件服务。 最新一期业绩显示，2024年三季报，公司实现营业收入6.35亿元，同比21.27% ...

Group 1 - The core viewpoint of the news is that Haocen Medical's stock has experienced a decline, with a closing price of 2.82 yuan and a market capitalization of 2.369 billion yuan, indicating a challenging market environment for the company [1] - On March 28, Haocen Medical saw a net inflow of 187,600 yuan in main funds, but over the past five days, there was a total outflow of 4.5704 million yuan, suggesting a negative trend in investor sentiment [1] - The company primarily engages in oral medical services and the research, production, and sales of permanent magnet switches and high/low voltage switchgear products, with key offerings including medical oral services, industrial switch products, and credit big data software services [1] Group 2 - For the latest financial performance, Haocen Medical reported a revenue of 635 million yuan for the third quarter of 2024, reflecting a year-on-year increase of 21.27%, while the net profit was 13.4967 million yuan, showing a year-on-year decrease of 17.31%, with a gross profit margin of 47.97% [1] - The company's price-to-earnings (PE) ratio (TTM) is -24.37, and the price-to-book (PB) ratio is 5.29, with a total market value of 2.369 billion yuan, which is significantly lower than the industry average PE of 48.41 and PB of 3.76 [2] - The industry median PE is 43.56 and median PB is 2.84, indicating that Haocen Medical is underperforming compared to its peers in the healthcare sector [2]

股东方面，截至2024年9月30日，皓宸医疗股东户数44932户，较上次增加3565户，户均持股市值35.28 万元，户均持股数量2.76万股。 皓宸医疗科技股份有限公司主要从事口腔医疗服务以及永磁开关及高低压开关成套设备产品的研发、生 产和销售。其主要产品有医疗口腔服务、实业开关产品、征信大数据软件服务。 皓宸医疗收盘下跌1.04%，最新市净率5.35，总市值 23.94亿元 3月25日，皓宸医疗今日收盘2.85元，下跌1.04%，最新市净率5.35，总市值23.94亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入6.35亿元，同比21.27%；净利润1349.67万元， 同比-17.31%，销售毛利率47.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10皓宸医疗-24.63-25.375.3523.94亿行业平均 44.4036.383.76164.34亿行业中值42.8133.422.9348.88亿1昭衍新药-17093.5039.311.95156.04亿2普瑞眼 科-196.3624.542.9665.76亿3何氏眼科-164.0050.281.6531.95亿4迪 ...

Revenue Projections - The estimated revenue for 2024 is projected to be between 800 million and 900 million CNY, compared to 756.71 million CNY in the same period last year, indicating a growth of approximately 5.7% to 18.8%[3] Profit and Loss Expectations - The net profit attributable to shareholders is expected to be a loss of between 40 million and 22 million CNY, an improvement from a loss of 94.37 million CNY in the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 20 million and 11 million CNY, compared to a loss of 85.10 million CNY last year, showing a significant reduction in losses[3] - The basic earnings per share is expected to be a loss of between 0.0476 CNY and 0.0262 CNY, improving from a loss of 0.1123 CNY per share in the previous year[3] Operational Performance - The company has seen continuous growth in revenue from oral medical services and permanent magnet switch business, contributing to overall operational quality improvement[5] Investment Income and Risk Management - The decline in investment income is attributed to the impairment provisions made by the company's associate, Fushun Bank, to enhance risk resistance capabilities[5] - The company plans to recognize overdue interest based on prudence due to ongoing litigation matters, contributing to the overall expected loss for 2024[5] Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed financial information to be disclosed in the 2024 annual report[7]

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-042 特此公告。 皓宸医疗科技股份有限公司董事会 二〇二四年十二月三十日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开第 五届董事会第十一次会议、第五届监事会第十一次会议，审议通过了《关于德伦 医疗 2023 年度业绩补偿方案的议案》，公司以现金方式购买的广东德伦医疗集团 有限公司（以下简称"德伦医疗"）51.00%股权，因德伦医疗未能完成 2023 年度 业绩承诺，业绩承诺方须按照约定履行补偿义务。 根据众华会计师事务所（特殊普通合伙）针对德伦医疗 2023 年度业绩完成情 况出具的《皓宸医疗科技股份有限公司实际盈利数与利润预测数差异情况专项审 核报告》（众会字（2024）第 03479 号），德伦医疗 2023 年度业绩实际数为 7,394.57 万元。截至 2023 年末德伦医疗累计实现业绩数为 5,593.51 万元，累计承诺业绩 金额 15,500.00 万元，扣除 2022 年度已补偿金额后的差额为 ...

表决结果：通过。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届监事会第十三次会 议于 2024 年 10 月 18 日以电子邮件的形式发出会议通知，会议于 2024 年 10 月 30 日上午 11:00 在公司会议室以现场结合通讯表决方式召开。会议应参加表决 监事 3 人，实际参加表决监事 3 人。会议由监事会主席刘月先生召集并主持，会 议的内容以及召集、召开的方式、程序均符合《中华人民共和国公司法》和《公 司章程》的规定。 经与会监事认真审议并表决，通过了以下议案： 一、审议通过《关于 2024 年第三季度报告的议案》 表决情况：同意 3 票，反对 0 票，弃权 0 票； 证券代码：002622 证券简称：皓宸医疗 公告编号：2024-040 皓宸医疗科技股份有限公司 第五届监事会第十三次会议决议公告 特此公告。 皓宸医疗科技股份有限公司监事会 二〇二四年十月三十日 经审核，监事会认为董事会编制和审核《皓宸医疗科技股份有限公司 2024 年第三季度报告》的程序符合法律、行政法规及中国证监会和深圳证券交易 ...

Financial Performance - Revenue for Q3 2024 reached ¥253,020,064.77, an increase of 20.48% year-over-year[2] - Net profit attributable to shareholders was ¥12,943,174.20, up 48.76% compared to the same period last year[2] - Net profit after deducting non-recurring gains and losses was ¥12,822,455.55, reflecting a 52.13% increase year-over-year[2] - Total operating revenue for Q3 2024 reached ¥635,030,298.87, an increase of 21.3% compared to ¥523,639,966.97 in the same period last year[20] - Operating profit for Q3 2024 was ¥31,450,295.28, down 8.0% from ¥34,527,160.94 in Q3 2023[21] - Net profit attributable to shareholders of the parent company was ¥13,496,659.38, a decrease of 17.4% from ¥16,321,536.90 in the previous year[22] - The company reported a decrease in comprehensive income attributable to shareholders of the parent company to ¥30,221,773.21 from ¥37,234,881.52 in the previous year[22] - Basic earnings per share for Q3 2024 were ¥0.0161, compared to ¥0.0194 in Q3 2023[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,565,747,164.97, representing a 1.94% increase from the end of the previous year[2] - The total assets of the company as of the latest report amount to CNY 1,565,747,164.97, an increase from CNY 1,535,890,599.57 at the beginning of the period[18] - The company's current liabilities total CNY 893,347,731.93, slightly up from CNY 891,757,164.96 at the beginning of the period[18] - Total liabilities increased to ¥1,073,322,431.77 from ¥1,070,747,639.58 year-over-year[19] - Shareholders' equity attributable to the parent company increased to ¥447,820,785.37, a rise of 3.47% compared to the end of last year[2] - The company’s total equity increased to ¥492,424,733.20, compared to ¥465,142,959.99 in Q3 2023[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥43,066,291.87, down 5.89% compared to the previous year[2] - The company reported a net cash flow from operating activities of ¥43,066,291.87, slightly down from ¥45,761,050.12 in Q3 2023[23] - Net cash flow from investment activities was -7,246,655.63, a decrease from 8,465,505.96 in the previous period[24] - Cash inflow from financing activities amounted to 78,400,000.00, significantly up from 17,000,000.00 in the prior period[24] - Cash outflow from financing activities totaled 103,754,320.53, compared to 39,356,135.12 previously[24] - The net cash flow from financing activities was -25,354,320.53, slightly worse than -22,356,135.12 in the last period[24] - The ending balance of cash and cash equivalents was 152,382,007.24, up from 150,098,941.99 at the end of the previous period[24] - The net increase in cash and cash equivalents for the quarter was 10,465,350.70, down from 31,870,420.96 in the previous quarter[24] Research and Development - R&D expenses decreased by ¥5,090,000, a reduction of 47.70% year-over-year[5] - Research and development expenses for Q3 2024 were ¥5,583,042.65, down from ¥10,675,860.37 in the same period last year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,932[8] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of the shares[8] - The second-largest shareholder, Shaanxi International Trust Co., holds 3.84% of the shares[8] Legal and Regulatory Issues - The company has disclosed multiple legal proceedings related to asset management disputes, with updates provided on various dates throughout 2024[10] - The company has reported that some bank accounts have been frozen, with ongoing updates on the situation[12] - The company is actively communicating with the Shanghai Financial Court regarding the execution procedures related to a legal case[11] - The company is facing uncertainty regarding control changes, as a lawsuit has been filed against it, and the outcome is pending[16] Asset Management and Freezing Issues - The company’s assets have been frozen due to a loan dispute, with the equity of its wholly-owned subsidiary, Zhiyu Medical, frozen for an amount of CNY 50 million, lasting for 1,097 days[14] - The total frozen bank balance of the company and its subsidiaries is CNY 574,164.23, accounting for 0.13% of the latest audited net assets[14] - The company is actively negotiating with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank to resolve the asset and account freezing issues through extension, installment repayment, and financing replacement[14] - The company’s largest shareholder, Huayin Rifen, has sent a notice indicating that the Shanghai Pudong Development Bank Guangzhou Branch has become the sole trustee of a specific asset management plan[15] Investment Risks - The company emphasizes the importance of investors being aware of investment risks[11] Audit Status - The company has not undergone an audit for the third quarter report[24]

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-039 《2024 年第三季度报告》详见公司指定信息披露媒体《中国证券报》、《上 海证券报》、《证券时报》及巨潮资讯网（www.cninfo.com.cn）2024 年 10 月 31 日公告。 皓宸医疗科技股份有限公司 二、备查文件 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十三次会 议于2024年10月30日上午10:00在公司会议室以现场结合通讯表决方式召开。 召开本次会议的通知已于 2024 年 10 月 18 日以电话、电子邮件等方式通知了各 位董事，会议应参加表决董事 7 名，实际参加表决董事 7 名。此次会议的召集、 召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法律、法 规的规定，合法有效。 一、审议通过《关于 2024 年第三季度报告的议案》 经与会董事认真审议并表决，通过了以下议案： 表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 1、《皓宸 ...